EXPERIENCE

Kevin has advised on a broad range of corporate transactions, including numerous public and private company mergers, acquisitions, asset sales, and investments.

Significant matters include representing:

• Callaway Golf in its:
  • US$2 billion stock-for-stock merger with Topgolf International
  • US$75 million acquisition of Ogio International
  • US$125 million acquisition of TravisMathew
  • €418 million acquisition of German-based Jack Wolfskin
  • US$29 million acquisition of BigShots Golf
• Extra Space Storage in its:
  • US$47 billion stock-for-stock merger with Life Storage
  • US$590 million acquisition of Storage Express
  • US$1.4 billion acquisition of SmartStop Self Storage
• Bridge Investment Group in its US$320 million acquisition of Newbury Partners
• Viasat in its:
  • US$222 million stock-for-stock merger with RigNet
  • US$62 million acquisition of NetNearU
• BioMed Realty Trust in its US$8 billion acquisition by affiliates of The Blackstone Group
• Impact Biomedicines in its acquisition by Celgene Corporation for up to US$7 billion
• Alphatec Spine in its:
  • Acquisition of French-based EOS imaging via public tender
  • US$80 million sale of its international business to Globus Medical
• Excel Trust in its US$2 billion acquisition by affiliates of The Blackstone Group
• Ligand Pharmaceuticals in its US$178 million acquisition of Open Monoclonal Technology
• Agility Clinical in its sale to Precision Medical Group for proceeds of up to US$46 million
• Aratana Therapeutics in its:
  • €33.3 million stock acquisition of Okapi Sciences
  • US$30 million cash and stock merger with Vet Therapeutics
• Neurelis in its acquisition of Aegis Therapeutics
• Pulse Electronics in a US$26 million going private transaction with Oaktree Capital Management
• Zavante Therapeutics in its stock-for-stock sale to Nabriva Therapeutics plc for up to US$125 million

Kevin has also advised numerous companies, underwriters, and investors on various public and private financings, including initial public offerings, PIPE financings, venture financings, private equity and debt offerings, and follow-on, and secondary public offerings, including representing:

• Bridge Investment Group in its US$300 million initial public offering
• Callaway Golf in connection with its follow-on offerings of equity and debt, raising more than US$250 million
• Crinetics Pharmaceuticals in its US$117 million initial public offering and several equity follow-on offerings and private placement financings
• Essex Property Trust in senior notes offerings and at-the-market equity offerings, raising more than US$2 billion
• Extra Space Storage in equity and debt offerings, raising more than US$875 million
• Gossamer Bio in its US$317 million initial public offering and several equity and debt follow-on offerings and private placement financings
• Neurelis in its preferred stock financings with LYZZ Capital, HBM Healthcare Investments, and China Medical Systems, raising over US$150 million
• SkyWest Airlines in connection with various capital raising matters
• Viasat in equity and debt offerings, raising more than US$1 billion
• Virgin Galactic Holdings in its at-the-market equity offerings
• Airgain in its US$12 million initial public offering
• Alphatec Spine in multiple PIPE financings, raising over US$150 million
• Zavante Therapeutics in its Series A financing with Frazier Healthcare Partners, Longitude Capital, and Aisling Capital
• A number of investment banks, including Barclays, BofA Merrill Lynch, BMO, Jefferies, J.P Morgan, Piper Jaffray, and Stifel, in public offerings of equity securities for life sciences companies, including Applied Genetic Technologies Corporation, Glycomimetics, ACADIA Pharmaceuticals, Biocryst Pharmaceuticals, Clovis Oncology, Mirati Therapeutics, Neurocrine Biosciences, and Sarepta Therapeutics